CHF Solutions, Inc. to Exhibit at the 23rd Annual Scientific Meeting of the Heart Failure Society of America
September 10 2019 - 8:00AM
CHF Solutions, Inc. (Nasdaq:CHFS) today announced it would be
exhibiting at the 23rd Annual Scientific Meeting of the Heart
Failure Society of America from September 14-16, 2019. The
conference is being held at the Pennsylvania Convention Center and
Philadelphia Marriott Downtown in Philadelphia, PA. The company
will be exhibiting at booth #217 in the Pennsylvania Convention
Center.
About CHF SolutionsCHF
Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused
on developing, manufacturing and commercializing the Aquadex
FlexFlow® system for aquapheresis therapy. The Aquadex FlexFlow
system is a clinically proven therapy that provides a safe,
effective, and predictable method of removing excess sodium and
fluid from patients suffering from fluid overload. The Aquadex
FlexFlow system is indicated for temporary (up to eight hours)
ultrafiltration treatment of patients with fluid overload who have
failed diuretic therapy, and extended (longer than 8 hours)
ultrafiltration treatment of patients with fluid overload who have
failed diuretic therapy and require hospitalization. All treatments
must be administered by a healthcare provider, under physician
prescription, both of whom having received training in
extracorporeal therapies. The company is dedicated to changing the
lives of patients suffering from fluid overload through science,
collaboration, and innovative. CHF Solutions is a Delaware
corporation headquartered in Minneapolis, Minnesota with wholly
owned subsidiaries in Australia and Ireland. The company has been
listed on the Nasdaq Capital Market since February 2012.
Forward-Looking
StatementsCertain statements in this release are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding its activities in connection with
the 23rd Annual Scientific Meeting of the Heart Failure Society of
America. Forward-looking statements are predictions, projections
and other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercialization strategy, the
possibility that we may be unable to raise sufficient funds
necessary for our anticipated operations, our post-market clinical
data collection activities, benefits of our products to patients,
our expectations with respect to product development and
commercialization efforts, our ability to increase market and
physician acceptance of our products, potentially competitive
product offerings, intellectual property protection, our ability to
integrate acquired businesses, our expectations regarding
anticipated synergies with and benefits from acquired businesses,
and other risks and uncertainties described in our filings with
the SEC. Forward-looking statements speak only as of the date
when made. CHF Solutions does not assume any obligation
to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
CONTACTS:
INVESTORS: Claudia Napal
Drayton Chief Financial Officer CHF Solutions, Inc. 952-345-4205
ir@chf-solutions.com-or- Bret Shapiro Managing Partner CORE IR
516-222-2560 brets@coreir.com www.coreir.comMEDIA
Jules Abraham JQA Partners, Inc. 917-885-7378
jabraham@jqapartners.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024